These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 1854593

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer.
    Yano T, Sugio K, Yamazaki K, Kase S, Yamaguchi M, Ondo K, Yoshino I, Sugimachi K.
    Lung Cancer; 1999 Dec; 26(3):143-8. PubMed ID: 10598924
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial.
    Yeung AW, Pang YK, Tsang YC, Wong SW, Leung JS.
    Cancer; 1993 Jun 01; 71(11):3633-9. PubMed ID: 8387882
    [Abstract] [Full Text] [Related]

  • 6. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y, Tanaka T, Tanji Y, Fujiwara A, Taguchi T.
    Biotherapy; 1994 Jun 01; 8(1):41-50. PubMed ID: 7547080
    [Abstract] [Full Text] [Related]

  • 7. Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Eberlein TJ, Rodrick ML, Massaro AF, Jung SE, Mannick JA, Schoof DD.
    Cancer Immunol Immunother; 1989 Jun 01; 30(3):145-50. PubMed ID: 2598183
    [Abstract] [Full Text] [Related]

  • 8. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y.
    Hum Cell; 1992 Sep 01; 5(3):226-35. PubMed ID: 1467321
    [Abstract] [Full Text] [Related]

  • 9. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y.
    Hokkaido Igaku Zasshi; 1992 Jul 01; 67(4):475-87. PubMed ID: 1330859
    [Abstract] [Full Text] [Related]

  • 10. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T, Nomura K, Hasegawa M, Ishikura K, Kubo T.
    Br J Urol; 1994 Jan 01; 73(1):23-31. PubMed ID: 8298895
    [Abstract] [Full Text] [Related]

  • 11. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
    Munari L, Silvani A, Passerini CG, Radrizzani M, Parmiani G, Boiardi A.
    J Neurosurg Sci; 1990 Jan 01; 34(3-4):283-8. PubMed ID: 1965907
    [Abstract] [Full Text] [Related]

  • 12. Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.
    Rodolfo M, Salvi C, Bassi C, Parmiani G.
    Cancer Immunol Immunother; 1990 Jan 01; 31(1):28-36. PubMed ID: 2306753
    [Abstract] [Full Text] [Related]

  • 13. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 Jan 01; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

  • 14. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
    Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE.
    J Clin Oncol; 1990 Oct 01; 8(10):1618-29. PubMed ID: 2213099
    [Abstract] [Full Text] [Related]

  • 15. [A study to increase the therapeutic effects of adoptive immunotherapy in vivo. Influence on the generation of lymphokine activated killer (LAK) cells and therapeutic effects of LAK cells with anti-tumor drug (cyclophosphamide)].
    Yoshimori K.
    Nihon Ika Daigaku Zasshi; 1992 Oct 01; 59(5):418-27. PubMed ID: 1430114
    [Abstract] [Full Text] [Related]

  • 16. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
    Nomura K, Fujioka T.
    Nihon Hinyokika Gakkai Zasshi; 1993 May 01; 84(5):831-40. PubMed ID: 8320888
    [Abstract] [Full Text] [Related]

  • 17. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T.
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar 01; 82(3):395-404. PubMed ID: 2072602
    [Abstract] [Full Text] [Related]

  • 18. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
    Liu X.
    Zhonghua Zhong Liu Za Zhi; 1993 May 01; 15(3):205-8. PubMed ID: 8261867
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.